Kern Pharma launches Herzuma, the trastuzumab biosimilar

  • With this launch, Kern Pharma is positioned as the only laboratory that markets three biosimilar monoclonal antibodies in Spain and Portugal: Remsima® (infliximab), Truxima® (rituximab) and Herzuma® (trastuzumab)
  • The European Medicines Agency has approved this new biosimilar for the same therapeutic indications as the reference biological drug

Barcelona, ​​June 13, 2018.- Kern Pharma starts the commercialization of Herzuma®, the biosimilar of trastuzumab, thus becoming the only laboratory that makes available to patients and health professionals in Spain and Portugal three biosimilar monoclonal antibodies, thanks to its distribution agreement with the Korean biotechnology company Celltrion Healthcare. Herzuma® is a humanized monoclonal antibody approved by the European Medicines Agency (EMA) for the same therapeutic indications as the reference biologic drug: early breast cancer, metastatic breast cancer and metastatic gastric cancer. Herzuma®, with the same mechanism of action as the reference biological drug, has shown comparability in terms of efficacy and safety. 

For Manuel Garrido , CEO of Kern Pharma, "this new launch is a crucial step in the consolidation of our division of biosimilars, Kern Pharma Biologics, and positions us as a reference laboratory in this field. As a result of our commitment to innovation and the effort to make the latest therapies available to professionals and patients, we are the only Spanish company that commercialises three biosimilar monoclonal antibodies in the Iberian Peninsula. "  

The firm commitment of Kern Pharma for biosimilars 

The entry of Kern Pharma in the field of biosimilar medicines occurred in 2015, with the launch of Remsima® (infliximab), the first biosimilar monoclonal antibody (mAb) authorized by the EMA and indicated for the treatment of chronic inflammatory autoimmune diseases such as rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and psoriasis.

Two years later, in 2017, he launched his second biosimilar, Truxima® (rituximab), chimeric monoclonal antibody (mAb), also approved by EMA for the same therapeutic indications as the reference biologic drug: non-Hodgkin's lymphoma, lymphatic leukemia chronic, rheumatoid arthritis, granulomatosis with polyangiitis and microscopic polyangiitis. 

Since then, the company has continued working together with Celltrion Healthcare, one of the leading biotechnological manufacturers of this type of drugs and with the most experience in this field, in the launch of new biosimilar drugs. 

To read more Press Release articles, click here.